News - ASX Annoucements
30 Jan 2012
VGX-100 identified as potential new therapy for improving corneal graft survival
09 Jan 2012
Circadian commences first Phase 1 clinical trial of VEGF-C antibody VGX-100 in cancer patients
31 Oct 2011
Circadian receives FDA IND approval to begin clinical trials with VGX-100 for the treatment of cancer patients with solid tumors
10 Oct 2011
Healthscope commences clinical validation study of Circadian's Cancer Diagnostic
30 Sep 2011
Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors
16 Jun 2011
Circadian provides market update on clinical development plans for VGX-100 in oncology and eye disease indications
07 Jun 2011
VEGF-C and VEGF-D identified as biomarkers for Avastin resistance in colorectal cancer patients
18 Apr 2011
Circadian Technologies (Small Cap Showcase 2011) - Robert Klupacs Presentation
Read More
07 Apr 2011
Open Briefing with CEO & MD Robert Klupacs on First Phase I Clinical Trial of IMC - 3C5
06 Apr 2011
Circadian's VGX-100 Inhibits Tumour Growth in Models of Lung, Ovarian and Prostate Cancer
06 Apr 2011
Circadian's partner ImClone Systems commences first Phase 1 clinical trial of VEGFR-3 antibody IMC-3C5
22 Mar 2011
New issue announcement, application for quotation of additional securities and agreement
13 Jan 2011
Chugai Pharmaceutical of Japan Grants Circadian Worldwide Licence to its VEGF-D Intellectual Property Estate